

# Erratum to: “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation”

Iryna Lastovytska, Silke Heidenreich, Evgeny Klyuchnikov, Christian Niederwieser, Nico Gagelmann, Johanna Richter, Radwan Massoud, Kristin Rathje, Tetiana Perekhrestenko, Gaby Zeck, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis Ayuk and Nicolaus Kröger

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg-Eppendorf, Germany

**Correspondence:** N. Kröger  
nmkroeger@outlook.de

**Received:** November 3, 2025.

**Accepted:** November 3, 2025.

<https://doi.org/10.3324/haematol.2025.289363>

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



We have observed some errors in the recently published manuscript “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation”<sup>1</sup>

The correct cumulative incidence of chronic graft-versus-host disease (cGvHD) and the 95% Confidence Interval (95%CI) in the Abstract need to be corrected in the Results section and in Table 4A.

- In the Abstract, the 1-year cumulative incidence of cGvHD is correct as:  
Ruxolitinib: 49% (95%CI: 33-69%)  
Ruxolitinib + ECP: 24% (95%CI: 15-38%)
- In the Results section, it is:  
Ruxolitinib: 41% (95%CI: 31-67%); this should be corrected to 49% (95%CI: 33-69%)  
Ruxolitinib + ECP: 24% (95%CI: 14-27%); this should be corrected to 24% (CI: 15-38%)
- In Table 4A, the 1-year cumulative incidence of cGvHD is:  
Ruxolitinib: 51 (33-69); this should be corrected to 49 (33-69)  
Ruxolitinib + ECP: 25% (95%CI: 15-38%); this should be corrected to 24 (15-38).

Correct sentence of the Results section and the correct Table are shown below.

## Chronic graft-versus-host disease, and chronic graft-versus-host disease, relapse-free survival and failure-free survival

At six and 12 months, 25% and 20% of evaluable patients

in the Ruxo-ECP cohort and 20% and 66% of evaluable patients in the Ruxo cohort experienced cGvHD, resulting in a cumulative incidence of cGvHD at one year of 24% (95%CI: 15-38%) after Ruxo-ECP and 49% (95%CI: 33-69%) after Ruxo.

**Correct Table 4.** Outcome of steroid-refractory-acute graft-versus-host disease.

**A.** All patients.

Outcome	Ruxo-ECP N=49 % (95%CI)	Ruxo alone N=29 % (95%CI)	P
1-year NRM	47 (34-65)	38 (22-57)	0.18
1-year relapse	10 (5-21)	21 (10-40)	0.1
2-year OS	36 (24-50)	38 (22-58)	0.75
1-year cGvHD	24 (15-38)	49 (33-69)	0.01

cGvHD: chronic graft-versus-host disease; ECP: extracorporeal photopheresis; N: number; NRM: non-relapse mortality; OS: overall survival; Ruxo: ruxolitinib; 95% CI: 95% Confidence Interval.

## References

---

1. I. Lastovytska, S. Heidenreich, E. Klyuchnikov, et al. Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation. *Haematologica* 2025;110(7):1536-1544.